XML 23 R9.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities:      
Net (loss) income $ (362) $ 16 $ 179
Adjustments to reconcile net (loss) income to net cash provided by operating activities:      
Depreciation and amortization 486 505 534
Deferred income taxes (116) 35 165
Stock-based compensation expense 17 22 20
Impairment and (gain) loss on sale of businesses, net 301 (87) 71
Gain from early extinguishment of debt (25) (72) (253)
Gain from CoreTrust Transaction     (119)
Other non-cash expenses, net 188 181 182
Changes in operating assets and liabilities, net of effects of acquisitions and divestitures:      
Patient accounts receivable (66) (193) 22
Supplies, prepaid expenses and other current assets (75) (82) (128)
Accounts payable, accrued liabilities and income taxes 137 (50) (158)
Other (5) (65) (215)
Net cash provided by operating activities 480 210 300
Cash flows from investing activities:      
Acquisitions of facilities and other related businesses (25) (38) (9)
Purchases of property and equipment (360) (467) (415)
Proceeds from disposition of hospitals and other ancillary operations 174 432 89
Proceeds from sale of property and equipment 5 28 38
Purchases of available-for-sale debt securities and equity securities (81) (137) (114)
Proceeds from sales of available-for-sale debt securities and equity securities 80 232 110
Purchases of investments in unconsolidated affiliates (9) (11) (19)
Distribution of CoreTrust Transaction proceeds     121
Increase in other investments (59) (65) (60)
Net cash used in investing activities (275) (26) (259)
Cash flows from financing activities:      
Repurchase of restricted stock shares for payroll tax withholding requirements (1) (4) (8)
Deferred financing costs and other debt-related costs (9) (3) (74)
Proceeds from noncontrolling investors in joint ventures 1 5 13
Redemption of noncontrolling investments in joint ventures (3) (1) (5)
Distributions to noncontrolling investors in joint ventures (155) (141) (125)
Other borrowings 25 39 48
Issuance of long-term debt 1,236 989 1,535
Proceeds from ABL Facility 3,763 3,176 542
Repayments of long-term indebtedness (5,063) (4,324) (2,356)
Net cash used in financing activities (206) (264) (430)
Net change in cash and cash equivalents (1) (80) (389)
Cash and cash equivalents at beginning of period 38 118 507
Cash and cash equivalents at end of period 37 38 118
Supplemental disclosure of cash flow information:      
Interest payments (741) (801) (835)
Income tax payments, net of refunds $ (171) $ (91) $ (6)